AstraZeneca(US:AZN) ZACKSยท2024-11-07 15:20Core Viewpoint - AstraZeneca is expected to report quarterly earnings of $1.01 per share, reflecting a year-over-year increase of 16.1%, with revenues projected at $13.04 billion, up 13.5% from the previous year [1] Earnings Projections - Analysts have revised the consensus EPS estimate downward by 0.2% in the past 30 days, indicating a reassessment of initial estimates [1][2] - Changes in earnings projections are crucial for predicting investor reactions and short-term stock price movements [2] Key Metrics Projections - 'Rare Disease- Kanuma- World' is projected to reach $49.82 million, a year-over-year increase of 13.2% [4] - 'BioPharmaceuticals- CVRM- roxadustat- World' is estimated at $86.36 million, reflecting a 16.7% increase [4] - 'Oncology- Enhertu- World' is expected to reach $134.73 million, showing a significant year-over-year change of 84.6% [4] - 'Oncology- Orpathys- World' is forecasted at $13.76 million, indicating a 14.7% increase [5] - 'BioPharmaceuticals- R&I- U.S.' is projected to reach $663.15 million, up 8.9% from the prior year [5] - 'Oncology- Tagrisso- Europe' is expected to come in at $325.44 million, reflecting a 15.8% increase [5] - 'Oncology- Imfinzi- Europe' is projected at $275.17 million, indicating a 32.3% increase [6] - 'Oncology- Lynparza- Europe' is expected to reach $201.95 million, a 13.5% increase [6] - 'Oncology- Calquence- Europe' is forecasted at $146.85 million, reflecting a 14.7% increase [6] - 'Oncology- Enhertu- Europe' is projected to reach $27.56 million, indicating a year-over-year change of 72.3% [7] - 'Oncology- Zoladex- Europe' is expected to reach $31.50 million, reflecting a 1.6% increase [7] - The average prediction for 'Oncology- Europe' is $1.02 billion, indicating a 20.3% year-over-year change [7] Stock Performance - AstraZeneca shares have decreased by 17.6% in the past month, contrasting with the Zacks S&P 500 composite's increase of 3.2% [8] - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [8]